BTMD Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of 7.43% compared to Biote's net margin of -1.05%. Biote's return on equity of -- beat Astrana Health's return on equity of 9.13%.

Biote has a consensus price target of $7.47, signalling upside risk potential of 123.55%. On the other hand Astrana Health has an analysts' consensus of $50.5000 which suggests that it could grow by 57.13%. Given that Biote has higher upside potential than Astrana Health, analysts believe Biote is more attractive than Astrana Health.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Astrana Health has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.209%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Biote's is not.

Biote quarterly revenues are $49.8M, which are smaller than Astrana Health quarterly revenues of $665.2M. Biote's net income of $3.7M is higher than Astrana Health's net income of -$7M. Notably, Biote's price-to-earnings ratio is 18.56x while Astrana Health's PE ratio is 36.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.58x versus 0.76x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of 7.43% compared to Biote's net margin of 3.55%. Biote's return on equity of -- beat Cryo-Cell International's return on equity of --.

Biote has a consensus price target of $7.47, signalling upside risk potential of 123.55%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 74.4%. Given that Biote has higher upside potential than Cryo-Cell International, analysts believe Biote is more attractive than Cryo-Cell International.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.595%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 10.26% to investors and pays a quarterly dividend of $0.25 per share. Biote pays 150.27% of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Biote quarterly revenues are $49.8M, which are larger than Cryo-Cell International quarterly revenues of $8M. Biote's net income of $3.7M is higher than Cryo-Cell International's net income of $282.9K. Notably, Biote's price-to-earnings ratio is 18.56x while Cryo-Cell International's PE ratio is 487.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.58x versus 1.24x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

Omnicell has a net margin of 7.43% compared to Biote's net margin of -2.6%. Biote's return on equity of -- beat Omnicell's return on equity of 1.73%.

Biote has a consensus price target of $7.47, signalling upside risk potential of 123.55%. On the other hand Omnicell has an analysts' consensus of $42.17 which suggests that it could grow by 71.2%. Given that Biote has higher upside potential than Omnicell, analysts believe Biote is more attractive than Omnicell.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Omnicell has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.397%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omnicell offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. Omnicell pays out -- of its earnings as a dividend.

Biote quarterly revenues are $49.8M, which are smaller than Omnicell quarterly revenues of $269.7M. Biote's net income of $3.7M is higher than Omnicell's net income of -$7M. Notably, Biote's price-to-earnings ratio is 18.56x while Omnicell's PE ratio is 53.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.58x versus 1.01x for Omnicell. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of 7.43% compared to Biote's net margin of -12.84%. Biote's return on equity of -- beat P3 Health Partners's return on equity of -26.35%.

Biote has a consensus price target of $7.47, signalling upside risk potential of 123.55%. On the other hand P3 Health Partners has an analysts' consensus of $16.25 which suggests that it could grow by 88.52%. Given that Biote has higher upside potential than P3 Health Partners, analysts believe Biote is more attractive than P3 Health Partners.

Biote has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Biote has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biote pays 150.27% of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Biote quarterly revenues are $49.8M, which are smaller than P3 Health Partners quarterly revenues of $362.1M. Biote's net income of $3.7M is higher than P3 Health Partners's net income of -$46.5M. Notably, Biote's price-to-earnings ratio is 18.56x while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biote is 0.58x versus 0.02x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.